INS and diabetes mellitus: In summary, the long-term simulation results of this study using the IHE diabetes cohort model based on real-world effectiveness data of the drug and the latest drug price data in China showed that the use of IDegLira in Chinese patients with type 2 diabetes resulted in longer life-years and quality-adjusted life-years with lower direct healthcare costs compared with the use of GLP-1RA combined with basal insulin, making it a cost-effective treatment option.